ArticleReumatologia clinica
Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.
Article in Reumatologia clinica. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.Seminars in arthritis and rheumatism · 2021Pooled it
- The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Trial
- Article
- Evaluating of colchicine use patterns and attack frequency of familial Mediterranean fever patients in the COVID-19 pandemic.International journal of rheumatic diseases · 2023Article
- In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing.Journal of molecular modeling · 2023Article
- Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVID-19.Cardiology journal · 2023Review
- Phytochemicals in the Prevention and Treatment of SARS-CoV-2-Clinical Evidence.Antibiotics (Basel, Switzerland) · 2022Review
- Clinical course of Covid-19 in a cohort of patients with Behçet disease.Medicina clinica (English ed.) · 2022Article
- Clinical course of Covid-19 in a cohort of patients with Behçet disease.Medicina clinica · 2022Article
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
- Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.Current research in translational medicine · 2021Review
- The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study.Annals of medicine and surgery (2012) · 2021Article
- Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Do inflammasome impact COVID-19 severity?Virusdisease · 2021Review
- Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.PloS one · 2021Observational
- Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.Frontiers in pharmacology · 2021Review
- The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time.Frontiers in medicine · 2021Review
- Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.Therapeutic advances in musculoskeletal disease · 2021Article
- Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines.Trends in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.